HomeCompareSNBIF vs EQR

SNBIF vs EQR: Dividend Comparison 2026

SNBIF yields 12.16% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 SNBIF wins by $4.1K in total portfolio value
10 years
SNBIF
SNBIF
● Live price
12.16%
Share price
$16.45
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$44.6K
Annual income
$2,595.30
Full SNBIF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — SNBIF vs EQR

📍 SNBIF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodSNBIFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, SNBIF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
SNBIF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SNBIF
Annual income on $10K today (after 15% tax)
$1,033.43/yr
After 10yr DRIP, annual income (after tax)
$2,206.01/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, EQR beats the other by $1,040.66/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SNBIF + EQR for your $10,000?

SNBIF: 50%EQR: 50%
100% EQR50/50100% SNBIF
Portfolio after 10yr
$42.5K
Annual income
$3,207.45/yr
Blended yield
7.54%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

SNBIF
Analyst Ratings
1
Sell
Consensus: Sell
Altman Z
60.9
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SNBIF buys
0
EQR buys
0
No recent congressional trades found for SNBIF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricSNBIFEQR
Forward yield12.16%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$44.6K$40.5K
Annual income after 10y$2,595.30$3,819.61
Total dividends collected$18.9K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusSellHold

Year-by-year: SNBIF vs EQR ($10,000, DRIP)

YearSNBIF PortfolioSNBIF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$11,916$1,215.81$11,248$547.57+$668.00SNBIF
2$14,104$1,353.95$12,701$666.53+$1.4KSNBIF
3$16,589$1,497.73$14,405$814.59+$2.2KSNBIF
4$19,396$1,646.38$16,413$999.84+$3.0KSNBIF
5$22,553$1,799.08$18,795$1,232.92+$3.8KSNBIF
6$26,087$1,955.04$21,639$1,527.95+$4.4KSNBIF
7$30,027$2,113.43$25,057$1,903.80+$5.0KSNBIF
8$34,402$2,273.44$29,197$2,385.87+$5.2KSNBIF
9$39,244$2,434.31$34,250$3,008.70+$5.0KSNBIF
10$44,587$2,595.30$40,467$3,819.61+$4.1KSNBIF

SNBIF vs EQR: Complete Analysis 2026

SNBIFStock

SanBio Company Limited develops, produces, and sells regenerative cell medicines for the central nervous system. The company develops SB623 that has completed a phase 2 clinical trial to treat traumatic brain injury in the United States and Japan. Its research pipeline products also comprise SB623 for ischemic and hemorrhagic strokes, age-related macular degeneration, retinitis pigments, spinal cord injury, Parkinson's disease, Alzheimer's disease, and others; SB618 for peripheral nerve damage; SB308 for muscular dystrophy disease; MSC1 for cancer; and MSC2 for inflammatory disease and optic neuritis. The company was founded in 2001 and is headquartered in Tokyo, Japan.

Full SNBIF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this SNBIF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SNBIF vs SCHDSNBIF vs JEPISNBIF vs OSNBIF vs KOSNBIF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.